ES2101421T3 - Amidas de acidos carboxilicos heterociclicos sustituidos, su preparacion y su utilizacion como medicamentos. - Google Patents

Amidas de acidos carboxilicos heterociclicos sustituidos, su preparacion y su utilizacion como medicamentos.

Info

Publication number
ES2101421T3
ES2101421T3 ES94117018T ES94117018T ES2101421T3 ES 2101421 T3 ES2101421 T3 ES 2101421T3 ES 94117018 T ES94117018 T ES 94117018T ES 94117018 T ES94117018 T ES 94117018T ES 2101421 T3 ES2101421 T3 ES 2101421T3
Authority
ES
Spain
Prior art keywords
preparation
medicines
carboxylic acid
acid amides
cyclic carboxylic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94117018T
Other languages
English (en)
Inventor
Klaus Dr Weidmann
Karl-Heinz Dr Baringhaus
Georg Dr Tschank
Martin Dr Bickel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE4337271A external-priority patent/DE4337271A1/de
Priority claimed from DE19944410881 external-priority patent/DE4410881A1/de
Priority claimed from DE19944433928 external-priority patent/DE4433928A1/de
Application filed by Hoechst AG filed Critical Hoechst AG
Application granted granted Critical
Publication of ES2101421T3 publication Critical patent/ES2101421T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A COMPUESTOS DE LA FORMULA I, UN PROCEDIMIENTO PARA SU ELABORACION ASI COMO SU UTILIZACION COMO MEDICAMENTO. LOS COMPUESTOS SE UTILIZAN EN PARTICULAR PARA LA INHIBICION DE LA BIOSINTESIS DE COLAGENO, COMO INHIBIDORES DE PROLILHIDROXILASA Y COMO FIBROSUPRESORES.
ES94117018T 1993-11-02 1994-10-27 Amidas de acidos carboxilicos heterociclicos sustituidos, su preparacion y su utilizacion como medicamentos. Expired - Lifetime ES2101421T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE4337271A DE4337271A1 (de) 1993-11-02 1993-11-02 Substituierte heterocyclische Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
DE19944410881 DE4410881A1 (de) 1994-03-29 1994-03-29 Substituierte heterocyclische Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
DE19944433928 DE4433928A1 (de) 1994-09-23 1994-09-23 Substituierte heterocyclische Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel

Publications (1)

Publication Number Publication Date
ES2101421T3 true ES2101421T3 (es) 1997-07-01

Family

ID=27205714

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94117018T Expired - Lifetime ES2101421T3 (es) 1993-11-02 1994-10-27 Amidas de acidos carboxilicos heterociclicos sustituidos, su preparacion y su utilizacion como medicamentos.

Country Status (20)

Country Link
EP (1) EP0650961B1 (es)
JP (1) JPH07228571A (es)
KR (1) KR950014072A (es)
CN (1) CN1107145A (es)
AT (1) ATE149486T1 (es)
AU (1) AU676775B2 (es)
CA (1) CA2134866A1 (es)
CY (1) CY2120B1 (es)
CZ (1) CZ289356B6 (es)
DE (1) DE59401924D1 (es)
DK (1) DK0650961T3 (es)
ES (1) ES2101421T3 (es)
GR (1) GR3023174T3 (es)
HK (1) HK1006711A1 (es)
IL (1) IL111454A (es)
MY (1) MY112413A (es)
NO (1) NO301880B1 (es)
NZ (1) NZ264821A (es)
PL (1) PL179794B1 (es)
TW (1) TW399046B (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL135495A (en) * 1995-09-28 2002-12-01 Hoechst Ag Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid
DE19746287A1 (de) * 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
FR2803592A1 (fr) * 2000-01-06 2001-07-13 Aventis Cropscience Sa Nouveaux derives de l'acide 3-hydroxypicolinique, leur procede de preparation et compositions fongicides les contenant.
DE50206476D1 (de) 2001-05-08 2006-05-24 Schering Ag Cyanoanthranylamid-derivate und deren verwendung als arzneimittel
DE10123573B4 (de) * 2001-05-08 2005-06-02 Schering Ag N-Oxidanthranylamid-Derivate und deren Verwendung als Arzneimittel
DE10123587B4 (de) * 2001-05-08 2005-04-07 Schering Ag Cyanoanthranylamid-Derivate und deren Verwendung als Arzneimittel
CN101664551B (zh) * 2001-12-06 2013-08-14 法布罗根股份有限公司 低氧诱导因子(HIF)α的稳定化
DK2298301T3 (en) 2001-12-06 2018-10-01 Fibrogen Inc MEDICINALS FOR TREATMENT OF ANEMIA ASSOCIATED WITH Kidney Disease
EP2295060B1 (en) 2001-12-06 2018-10-31 Fibrogen, Inc. Treatment or prevention of ischemic or hypoxic conditions
US7615565B2 (en) 2002-07-31 2009-11-10 Bayer Schering Pharma Aktiengesellschaft VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines
US7618940B2 (en) 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
CN102977016B (zh) 2003-06-06 2015-01-14 菲布罗根有限公司 含氮杂芳基化合物及其在增加内源性促红细胞生成素中的用途
EP1657241A1 (en) 2004-11-03 2006-05-17 Schering Aktiengesellschaft Novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors
US7906533B2 (en) 2004-11-03 2011-03-15 Bayer Schering Pharma Ag Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
EP1655295A1 (en) 2004-11-03 2006-05-10 Schering Aktiengesellschaft Anthranilamide pyridinureas as VEGF receptor kinase inhibitors
JP4792048B2 (ja) 2005-03-02 2011-10-12 ファイブロゲン インコーポレイティッド チエノピリジン化合物およびその使用方法
AU2006254897A1 (en) * 2005-06-06 2006-12-14 Fibrogen, Inc. Improved treatment for anemia using a HIF-alpha stabilising agent
KR20080028918A (ko) 2005-06-15 2008-04-02 피브로겐, 인크. 암의 치료를 위한 화합물과 방법
ZA200806752B (en) 2006-01-27 2009-10-28 Fibrogen Inc Cyanoisoquinoline compounds that stabilize hypoxia inducible factor (HIF)
KR101084635B1 (ko) * 2006-04-04 2011-11-18 피브로겐, 인크. Ｈｉｆ 조절제로서 피롤로- 및 티아졸로-피리딘 화합물
KR101130592B1 (ko) 2006-06-26 2012-04-02 워너 칠콧 컴퍼니 엘엘씨 프롤릴 히드록실라제 저해제 및 사용 방법
US8962530B2 (en) 2007-06-27 2015-02-24 Regents Of The University Of Colorado Inflammatory bowel disease therapies
AU2008302746B2 (en) * 2007-09-20 2014-07-03 Amgen Inc. 1-(4-(benzylbenzamid0) -benzyl) azetidine-3-carboxylic acid derivatives and related compounds as SlP receptor modulators for the treatment of immune disorders
EP2370422B1 (en) 2008-11-14 2019-06-05 Fibrogen, Inc. Thiochromene derivatives as hif hydroxylase inhibitors
KR101007675B1 (ko) * 2010-08-13 2011-01-13 김병두 보조 캡 이 부착된 플라즈마 용사 건 및 이를 활용하는 플라즈마 용사 시스템
KR101007674B1 (ko) * 2010-08-13 2011-01-13 김병두 보조 캡이 부착된 고속용사 건 및 코팅장치
NO2686520T3 (es) 2011-06-06 2018-03-17
US9409892B2 (en) 2012-03-09 2016-08-09 Fibrogen, Inc. 4-hydroxy-isoquinoline compounds as HIF hydroxylase inhibitors
JP6114958B2 (ja) 2012-07-04 2017-04-19 アグロカネショウ株式会社 ２−アミノニコチン酸エステル誘導体およびこれを有効成分とする殺菌剤
JP6196671B2 (ja) 2012-07-16 2017-09-13 フィブロジェン インコーポレイテッド イソキノリン化合物を作製する方法
DK2872488T3 (en) 2012-07-16 2018-10-29 Fibrogen Inc CRYSTALLINIC FORMS OF A PROLYL HYDROXYLASE INHIBITOR
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
CA2899024C (en) 2013-01-24 2022-01-04 Fibrogen, Inc. Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid
JP6604941B2 (ja) 2013-06-06 2019-11-13 フィブロジェン インコーポレイテッド Ｈｉｆプロリルヒドロキシラーゼ阻害剤の医薬製剤
NZ753904A (en) 2013-06-13 2020-07-31 Akebia Therapeutics Inc Compositions and methods for treating anemia
RU2021125455A (ru) 2013-11-15 2021-10-05 Экебиа Терапьютикс, Инк. Твердые формы { [5-(3-хлорфенил)-3-гидроксипиридин-2-карбонил]амино} уксусной кислоты, их композиции и применения
EP3247355A4 (en) 2015-01-23 2018-06-13 Akebia Therapeutics, Inc. Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
CN106146395B (zh) * 2015-03-27 2019-01-01 沈阳三生制药有限责任公司 3-羟基吡啶化合物、其制备方法及其制药用途
LT3277270T (lt) 2015-04-01 2022-01-10 Akebia Therapeutics, Inc. Kompozicijos ir būdai skirti anemijos gydymui
MX2020011845A (es) 2018-05-09 2021-01-15 Akebia Therapeutics Inc Proceso para preparar acido 2-[[5-(3-clorofenil)-3-hidroxipiridina -2-carbonil]amino]acetico.
KR20210057014A (ko) * 2018-09-13 2021-05-20 깃세이 야쿠힌 고교 가부시키가이샤 이미다조피리디논 화합물
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4015255A1 (de) 1990-05-12 1991-11-14 Hoechst Ag Oxalyl-aminosaeurederivate, verfahren zu ihrer herstellung und ihrer verwendung als arzneimittel zur inhibierung der prolyl-hydroxylase
EP0541042A1 (de) * 1991-11-05 1993-05-12 Hoechst Aktiengesellschaft Pyridin-2,4- und 2,5-dicarbonsäureamide und deren Derivate, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
RU2126794C1 (ru) * 1992-03-11 1999-02-27 Нархекс Лимитед Аминопроизводные оксо- или гидроксизамещенных гидразинов, способ их получения и фармацевтические композиции для ингибирования ретровирусной протеазы
TW352384B (en) * 1992-03-24 1999-02-11 Hoechst Ag Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals

Also Published As

Publication number Publication date
NO944162L (no) 1995-05-03
PL305646A1 (en) 1995-05-15
DE59401924D1 (de) 1997-04-10
NO301880B1 (no) 1997-12-22
IL111454A0 (en) 1994-12-29
AU676775B2 (en) 1997-03-20
GR3023174T3 (en) 1997-07-30
HK1006711A1 (en) 1999-03-12
DK0650961T3 (da) 1997-09-15
CY2120B1 (en) 2002-04-26
EP0650961A1 (de) 1995-05-03
ATE149486T1 (de) 1997-03-15
MY112413A (en) 2001-06-30
CZ289356B6 (cs) 2002-01-16
PL179794B1 (pl) 2000-10-31
NO944162D0 (no) 1994-11-01
AU7756494A (en) 1995-05-18
CN1107145A (zh) 1995-08-23
NZ264821A (en) 1997-02-24
CZ268394A3 (en) 1995-05-17
IL111454A (en) 2001-08-08
CA2134866A1 (en) 1995-05-03
TW399046B (en) 2000-07-21
EP0650961B1 (de) 1997-03-05
KR950014072A (ko) 1995-06-15
JPH07228571A (ja) 1995-08-29

Similar Documents

Publication Publication Date Title
ES2101421T3 (es) Amidas de acidos carboxilicos heterociclicos sustituidos, su preparacion y su utilizacion como medicamentos.
ES2101420T3 (es) Esteres-amidas de acidos carboxilicos heterociclicos sustituidos, su preparacion y su utilizacion como medicamentos.
ES2102132T3 (es) Amidas de acidos carboxilicos heterociclicos sustituidos, su preparacion y su utilizacion como medicamentos.
MX9603520A (es) Derivados del acido hidroxamico y acido carboxilico, procesos para su preparacion y su uso.
TR199800849T2 (xx) Siklikle heterosiklik N-ikame edilmi� alfa-iminohidroksamla karbon asitleri
AU686104B2 (en) Substituted amidinonaphthyl ester derivatives
ATE140922T1 (de) 3- oder 4-glykosyloxybenzopyranderivat und dieses enthaltende antiallergisches mittel
ES2147499A1 (es) Derivados de acidos carboxilicos, metodo para su elaboracion y agentes terapeuticos que contienen estos compuestos.
ES2123796T3 (es) Derivados de acidos fosfono-succinicos y su utilizacion como medicamentos.
UA35554C2 (uk) Похідні хінолон- і нафтиридонкарбонової кислоти у вигляді суміші ізомерів або окремих ізомерів, фармацевтична композиція, що має антибактеріальну активність та проміжні сполуки

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 650961

Country of ref document: ES